Clinical Characteristics and Risk of Relapse for Patients with Stage I–II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy

Diffuse large b-cell lymphoma (DLBCL) is an aggressive and potentially curable lymphoma that presents itself as stage I–II in 30% of all cases. It is known that in these localized stages, 15–20% of patients treated without rituximab eventually relapse, but less data exist regarding rituximab era. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercadal, S, Climent, F, Domingo-Doménech, E, Oliveira, A, Romagosa, V, de Sevilla, A Fernández, González-Barca, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222304/
https://www.ncbi.nlm.nih.gov/pubmed/25512717
http://dx.doi.org/10.4137/CMBD.S12713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222304/
https://www.ncbi.nlm.nih.gov/pubmed/25512717
http://dx.doi.org/10.4137/CMBD.S12713

Ejemplares similares